Quarterly ResultMay 7, 2026, 04:10 PM
Personalis Q1 Clinical Test Volume +258%; Secures Lung Cancer Medicare Coverage
AI Summary
Personalis, Inc. reported its first quarter 2026 financial results, with total revenue decreasing to $15.5 million from $20.6 million year-over-year. Despite the overall revenue decline and widened net loss, clinical test volume surged 258% to 7,815 tests, driving clinical revenue to $1.4 million. The company secured Medicare coverage for lung cancer surveillance, marking its second major coverage decision in six months, and reaffirmed its full-year 2026 financial guidance, projecting a five-fold growth in clinical revenue.
Key Highlights
- Secured Medicare coverage for lung cancer surveillance, its second major coverage in six months.
- Q1 2026 total revenue decreased to $15.5 million from $20.6 million year-over-year.
- Q1 2026 clinical test volume surged 258% year-over-year to 7,815 tests.
- Q1 2026 clinical revenue increased to $1.4 million from $0.3 million year-over-year.
- Q1 2026 net loss widened to $(30.0) million from $(15.8) million year-over-year.
- Reaffirmed full-year 2026 total revenue guidance of $78.0 million to $80.0 million.
- Reaffirmed full-year 2026 clinical revenue guidance of $10.0 million to $11.0 million.
- Ended Q1 2026 with $233.2 million in cash, cash equivalents, and investments.